Aberrant proliferation of mesangial cells (MCs) is a key finding in progressive glomerular disease. TH1177 is a small molecule that has been shown to inhibit low-voltage activated T-type Ca(2+) channels (TCCs). The current study investigates the effect of TH1177 on MC proliferation in vitro and in vivo. The effect of Ca(2+) channel inhibition on primary rat MC proliferation in vitro was studied using the microculture tetrazolium assay and by measuring bromodeoxyuridine incorporation. In vivo, rats with Thy1 nephritis were treated with TH1177 or vehicle. Glomerular injury and average glomerular cell number were determined in a blinded fashion. Immunostaining for Ki-67 and phosphorylated ERK were also performed. The expression of TCC isoforms in healthy and diseased tissue was investigated using quantitative real-time PCR. TCC blockade caused a significant reduction in rat MC proliferation in vitro, whereas L-type inhibition had no effect. Treatment of Thy1 nephritis with TH1177 significantly reduced glomerular injury (P < 0.005) and caused a 49% reduction in glomerular cell number (P < 0.005) compared to the placebo. TH1177 also reduced Ki-67-positive and pERK-positive cells per glomerulus by 52% (P < 0.01 and P < 0.005, respectively). These results demonstrate that TH1177 inhibits MC proliferation in vitro and in vivo, supporting the hypothesis that TCC inhibition may be a useful strategy for studying and modifying MC proliferative responses to injury.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730775PMC
http://dx.doi.org/10.1016/j.ajpath.2013.04.029DOI Listing

Publication Analysis

Top Keywords

proliferation in vitro
16
thy1 nephritis
12
channel inhibition
8
in vitro in vivo
8
rat proliferation
8
glomerular injury
8
glomerular cell
8
cell number
8
th1177 reduced
8
th1177
6

Similar Publications

Article Synopsis
  • Pancreatic cancer features a dense tissue environment that hinders effective delivery of the chemotherapy drug gemcitabine, making treatment challenging.
  • A targeted drug delivery system was developed using gold nanoparticles and the anti-EGFR antibody cetuximab, combined with gemcitabine and polyethylene glycol to enhance drug delivery to pancreatic cancer and associated cells.
  • The new drug delivery system, particularly the PEGylated nanoconjugate ACG44P1000, showed improved effectiveness in reducing the viability of pancreatic cancer cells in lab tests, setting the stage for future studies on its potential to combat tumor growth and desmoplasia in living organisms.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!